Robotic Colonoscopy Moves Into the Colon: FDA Clears Triton 1: US FDA | September 2026

What’s New?

The FDA has granted 510(k) clearance to the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures throughout the colon.

The platform is cleared for screening, surveillance and therapeutic colonoscopy, including EMR and ESD.

In the first-in-human CARE 1 study (n=50), cecal intubation was achieved in 100% of patients.

No procedure-related adverse events were reported.

The adenoma detection rate was 54.2%.

Operator workload fell by 67% on the NASA-TLX scale, suggesting a potential ergonomic advantage.

However, CARE 1 was a small, single-arm study, with results currently available as conference data.

Why Does It Matter?

Robotics is moving beyond surgery into flexible endoscopy, potentially offering improved scope stability, ergonomics and a more controlled platform for complex colonic interventions.

GastroAGI Takeaway

This is an important technology milestone—not evidence that robotic colonoscopy is better than conventional colonoscopy. FDA 510(k) clearance establishes substantial equivalence, not clinical superiority. Larger comparative studies must now demonstrate whether improved ergonomics and stability translate into better procedural efficiency, advanced resection outcomes, safety or clinically meaningful patient benefit.